Sein métastatique HER2+ HER2CLIMB02 (SGNTUC-016) A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer Paris
Sein métastatique RH+ DESTINY-Breast06 (D9670C00001) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Paris, Saint-Cloud JEAN-YVES PIERGA, ETIENNE BRAIN
VADS M19-894 A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability,;Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy;Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Paris CHRISTOPHE LE TOURNEAU